Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease - Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- - Abliva to host conference call and webcast on Friday 19 July at 4:30 pm CET / 10:30 am ET – LUND, Sweden, July 18, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced...
Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024 LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it will host a virtual KOL event on Tuesday, May 21, 2024 at 10:00 AM ET / 4:00 PM CET, featuring Amel Karaa, MD (Massachusetts General Hospital), who will discuss the unmet medical need and current treatment landscape for patients with primary mitochondrial disease. There are currently n...
A director at Prosafe Se bought 6,000 shares at 157.000NOK and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
With the investigational new drug (IND) application approved by the FDA, Abliva is getting ready for the pivotal Phase II/III trial for its lead drug candidate KL1333, NAD+ modulator expected to increase cellular energy production in primary mitochondrial disorder (PMD) patients. Phase Ia/b data with first findings from treating patients were published in 2021. Abliva is now focused on finalising the regulatory approvals in other countries. Another major focus for the management is to establish ...
With the investigational new drug (IND) application approved by the FDA, Abliva is getting ready for the pivotal Phase II/III trial for its lead drug candidate KL1333, NAD+ modulator expected to increase cellular energy production in primary mitochondrial disorder (PMD) patients. Phase Ia/b data with first findings from treating patients were published in 2021. Abliva is now focused on finalising the regulatory approvals in other countries. Another major focus for the management is to establish ...
We have discontinued our coverage of Ocean Yield following KKR’s successful acquisition of 94% of Ocean Yield’s outstanding shares in the voluntary offer. KKR intends to complete a compulsory acquisition of the remaining shares in Ocean Yield. We withdrew our recommendation and target price on the stock on 13 September following the offer; our last published estimates should no longer be relied upon.
A director at Ocean Yield ASA sold 25,000 shares at 41.020NOK and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
This morning, Ocean Yield announced it has reached an agreement for KKR to launch a voluntary offer of NOK41/share. Aker ASA, holding 61.7% of the shares, has undertaken to accept the offer, and the board of directors recommends shareholders accept. The closing price on Friday was NOK32.5 and the offer price represents a 26% premium to the last close, a 38% premium to the average share price of the past six months and a 17% premium to our NOK35 SOTP (including USD50m value for the FPSO). Given D...
Ocean Yield announced this morning it has reached an agreement for KKR to launch a voluntary offer of NOK41/share. Aker, holding 61.7% of the shares, has undertaken to accept the offer, and the board of directors recommends shareholders to accept. The offer price is at a 26% premium to last close, and a 17% premium to our SOTP.
As Ambu pre-released its Q3 results and new FY guidance in early July, the main news was the delay of the aScope 5 Broncho, which comes when several new competitors are entering the market. We believe the delay will be short, and management is confident aScope 4 is still superior to peers. Otherwise, there was little news in the Q3 report, with the exception of strong Visualisation growth in the US. We reiterate our BUY and DKK295 target price.
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
We have updated our estimates following the Q2 report and recent deal announcements. In our view, the Q2 results confirmed the case, supporting our view that its solid balance sheet should allow Ocean Yield to execute on new acquisitions, in turn building up its distribution capacity. We do not consider these estimate changes to be material, and we have not changed our BUY recommendation. We reiterate our NOK37 target price.
Ahead of the white paper on Friday, the government provided more details on offshore wind development in Norway. The bottom-fixed areas will be developed without state-aid, and awards will follow an auction in early 2022. Floating areas will be awarded on qualitative criteria and receive government support (level not yet decided). Both areas will be split into 2–3 licences, which will allow multiple consortiums to be awarded. While we believe the planned sizes (in GW) allow for critical mass, th...
OCEAN YIELD (NO), a company active in the Marine Transportation industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 2 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date June 8, 2021, the closing price was NOK 30.00 and its potentia...
The initial licensing rounds for offshore wind acreage in Norway are lining up to be competitive, with several high-profile local companies/consortiums already having announced their intention to participate. In addition, we would expect traditional renewables producers and international E&P companies to take part. Currently there is limited clarity on how the licensing process will work, but more details are expected in a government white paper (‘Stortingsmelding’) on 11 June. Although the winn...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.